Glutathione S-transferase omega genes in Alzheimer and Parkinson disease risk, age-at-diagnosis and brain gene expression: An association study with mechanistic implications

Molecular Neurodegeneration

Volumn 7, Issue 1, 2012, Pages

  Allen, Mariet ^a   Zou, Fanggeng ^a   Chai, High Seng ^b   Younkin, Curtis S ^a   Miles, Richard ^a   Nair, Asha A ^b   Crook, Julia E ^a   Pankratz, V Shane ^b   Carrasquillo, Minerva M ^a   Rowley, Christopher N ^a   Nguyen, Thuy ^a   Ma, Li ^a   Malphrus, Kimberly G ^a   Bisceglio, Gina ^a   Ortolaza, Alexandra I ^a   Palusak, Ryan ^a   Middha, Sumit ^b   Maharjan, Sooraj ^b   Georgescu, Constantin ^a   Schultz, Debra ^b   Rakhshan, Fariborz ^b   Kolbert, Christopher P ^b   Jen, Jin ^b   Sando, Sigrid B ^c,d   Aasly, Jan O ^c,d   Barcikowska, Maria ^e   Uitti, Ryan J ^a   Wszolek, Zbigniew K ^a   Ross, Owen A ^a   Petersen, Ronald C ^b   Graff Radford, Neill R ^a   Dickson, Dennis W ^a   Younkin, Steven G ^a   Ertekin Taner, Nilüfer ^a   more..

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

^c TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^d NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^e MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

Author keywords

Association; Disease risk; Gene expression; GSTO genes

Indexed keywords

APOLIPOPROTEIN E4; GLUTATHIONE S TRANSFERASE OMEGA 1; GLUTATHIONE S TRANSFERASE OMEGA 2; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE M3; GLUTATHIONE TRANSFERASE M5; GLUTATHIONE TRANSFERASE T1; GLUTATHIONE TRANSFERASE T2; UNCLASSIFIED DRUG; GSTO1 PROTEIN, HUMAN; GSTO2 PROTEIN, HUMAN;

ADULT; AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; BRAIN; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENE LOCUS; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; GLUTATHIONE METABOLISM; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PARKINSON DISEASE; RISK ASSESSMENT; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; ENZYMOLOGY; FOLLOW UP; GENETICS; META ANALYSIS; MIDDLE AGED; RISK FACTOR;

AGE OF ONSET; AGED; AGED, 80 AND OVER; ALLELES; ALZHEIMER DISEASE; FOLLOW-UP STUDIES; GENE EXPRESSION; GENETIC PREDISPOSITION TO DISEASE; GLUTATHIONE TRANSFERASE; HUMANS; MIDDLE AGED; PARKINSON DISEASE; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS;

EID: 84859517209     PISSN: None     EISSN: 17501326     Source Type: Journal    
DOI: 10.1186/1750-1326-7-13     Document Type: Article

References (61)

1. Prefrontal cortex glutathione S-transferase levels in patients with bipolar disorder, major depression and schizophrenia. Gawryluk JW, Wang JF, Andreazza AC, Shao L, Yatham LN, Young LT, Int J Neuropsychopharmacol 2011 14 1069 1074 10.1017/S1461145711000617 21733244
2. Kauer-Sant'Anna M, Walz JC, Bond DJ, Goncalves CA, Young LT, Yatham LN: 3-Nitrotyrosine and glutathione antioxidant system in patients in the early and late stages of bipolar disorder. Andreazza AC, Kapczinski F, J Psychiatry Neurosci 2009 34 263 271 19568477
3. Genetic polymorphisms of glutathione S-transferases GSTM1, GSTT1, GSTP1 and GSTA1 as risk factors for schizophrenia. Gravina P, Spoletini I, Masini S, Valentini A, Vanni D, Paladini E, Bossu P, Caltagirone C, Federici G, Spalletta G, Bernardini S, Psychiatry Res 2011 187 454 456 10.1016/j.psychres.2010.10.008 21093063
4. Association of common copy number variants at the glutathione S-transferase genes and rare novel genomic changes with schizophrenia. Rodriguez-Santiago B, Brunet A, Sobrino B, Serra-Juhe C, Flores R, Armengol L, Vilella E, Gabau E, Guitart M, Guillamat R, et al. Mol Psychiatry 2010 15 1023 1033 10.1038/mp.2009.53 19528963
5. Glutathione S-transferase omega-1 modifies age-at-onset of Alzheimer disease and Parkinson disease. Li YJ, Oliveira SA, Xu P, Martin ER, Stenger JE, Scherzer CR, Hauser MA, Scott WK, Small GW, Nance MA, et al. Hum Mol Genet 2003 12 3259 3267 10.1093/hmg/ddg357 14570706 (Pubitemid 37541071)
6. Polymorphisms in glutathione S-transferase omega-1 and AD, vascular dementia, and stroke. Kolsch H, Linnebank M, Lutjohann D, Jessen F, Wullner U, Harbrecht U, Thelen KM, Kreis M, Hentschel F, Schulz A, et al. Neurology 2004 63 2255 2260 10.1212/01.WNL.0000147294.29309.47 15623683 (Pubitemid 40024333)
7. Revealing the role of glutathione S-transferase omega in age-at-onset of Alzheimer and Parkinson diseases. Li YJ, Scott WK, Zhang L, Lin PI, Oliveira SA, Skelly T, Doraiswamy MP, Welsh-Bohmer KA, Martin ER, Haines JL, et al. Neurobiol Aging 2006 27 1087 1093 10.1016/j.neurobiolaging.2005.05.013 15985314 (Pubitemid 43850638)
8. Al Chalabi A, Shaw CE: Association study on glutathione S-transferase omega 1 and 2 and familial ALS. van de Giessen E, Fogh I, Gopinath S, Smith B, Hu X, Powell J, Andersen P, Nicholson G, Amyotroph Lateral Scler 2008 9 81 84 10.1080/17482960701702553 18427999 (Pubitemid 351584033)
9. Polymorphisms in glutathione S-transferase omega-1 gene and increased risk of sporadic Alzheimer disease. Capurso C, Panza F, Seripa D, Frisardi V, Imbimbo BP, Verdile G, Vendemiale G, Pilotto A, Solfrizzi V, Rejuvenation Res 2010 13 645 652 10.1089/rej.2010.1052 20818931
10. A GSTM3 polymorphism associated with an etiopathogenetic mechanism in Alzheimer disease. Maes OC, Schipper HM, Chong G, Chertkow HM, Wang E, Neurobiol Aging 2010 31 34 45 10.1016/j.neurobiolaging.2008.03.007 18423940
11. Fine mapping of 10q and 18q for familial Alzheimer's disease in Caribbean Hispanics. Lee JH, Mayeux R, Mayo D, Mo J, Santana V, Williamson J, Flaquer A, Ciappa A, Rondon H, Estevez P, et al. Mol Psychiatry 2004 9 1042 1051 10.1038/sj.mp.4001538 15241431 (Pubitemid 39524293)
12. Results of a high-resolution genome screen of 437 Alzheimer's Disease families. Blacker D, Bertram L, Saunders AJ, Moscarillo TJ, Albert MS, Wiener H, Perry RT, Collins JS, Harrell LE, Go RC, et al. Hum Mol Genet 2003 12 23 32 10.1093/hmg/ddg007 12490529 (Pubitemid 36097712)
13. Age at onset in two common neurodegenerative diseases is genetically controlled. Li YJ, Scott WK, Hedges DJ, Zhang F, Gaskell PC, Nance MA, Watts RL, Hubble JP, Koller WC, Pahwa R, et al. Am J Hum Genet 2002 70 985 993 10.1086/339815 11875758 (Pubitemid 34259314)
14. Characterization of the omega class of glutathione transferases. Whitbread AK, Masoumi A, Tetlow N, Schmuck E, Coggan M, Board PG, Methods Enzymol 2005 401 78 99 16399380 (Pubitemid 43052387)
15. Glutathione s-transferase omega 1-1 is a target of cytokine release inhibitory drugs and may be responsible for their effect on interleukin-1beta posttranslational processing. Laliberte RE, Perregaux DG, Hoth LR, Rosner PJ, Jordan CK, Peese KM, Eggler JF, Dombroski MA, Geoghegan KF, Gabel CA, J Biol Chem 2003 278 16567 16578 10.1074/jbc.M211596200 12624100 (Pubitemid 36799518)
16. Glutathione S-transferase mu, omega, pi, and theta class variants and smoking in Parkinson's disease. Wahner AD, Glatt CE, Bronstein JM, Ritz B, Neurosci Lett 2007 413 274 278 10.1016/j.neulet.2006.11.053 17194543 (Pubitemid 46209513)
17. Influence of polymorphisms in the genes for cytokines and glutathione S-transferase omega on sporadic Alzheimer's disease. Nishimura M, Sakamoto T, Kaji R, Kawakami H, Neurosci Lett 2004 368 140 143 10.1016/j.neulet.2004.06.076 15351436 (Pubitemid 39194859)
18. Three SNPs in the GSTO1, GSTO2 and PRSS11 genes on chromosome 10 are not associated with age-at-onset of Alzheimer's disease. Ozturk A, Desai PP, Minster RL, Dekosky ST, Kamboh MI, Neurobiol Aging 2005 26 1161 1165 10.1016/j.neurobiolaging.2004.11.001 15917099 (Pubitemid 40726008)
19. Genetics of Alzheimer's disease: a centennial review. Ertekin-Taner N, Neurol Clin 2007 25 611 667 10.1016/j.ncl.2007.03.009 17659183 (Pubitemid 47058875)
20. Genetics of Alzheimer disease in the pre- and post-GWAS era. Ertekin-Taner N, Alzheimers Res Ther 2010 2 3 10.1186/alzrt26 20236449
21. Clinical genetics of Parkinson's disease and related disorders. Wider C, Wszolek ZK, Parkinsonism Relat Disord 2007 13 Suppl 3 229 S232 18267241
22. Genetic factors influencing age at onset in LRRK2-linked Parkinson disease. Golub Y, Berg D, Calne DB, Pfeiffer RF, Uitti RJ, Stoessl AJ, Wszolek ZK, Farrer MJ, Mueller JC, Gasser T, Fuchs J, Parkinsonism Relat Disord 2009 15 539 541 10.1016/j.parkreldis.2008.10.008 19041274
23. Clinical features of LRRK2 parkinsonism. Haugarvoll K, Wszolek ZK, Parkinsonism Relat Disord 2009 15 Suppl 3 205 S208 20082991
24. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Williams A, et al. Nat Genet 2009 41 1088 1093 10.1038/ng.440 19734902
25. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, Combarros O, Zelenika D, Bullido MJ, Tavernier B, et al. Nat Genet 2009 41 1094 1099 10.1038/ng.439 19734903
26. Genome-wide analysis of genetic loci associated with Alzheimer disease. Seshadri S, Fitzpatrick AL, Ikram MA, DeStefano AL, Gudnason V, Boada M, Bis JC, Smith AV, Carassquillo MM, Lambert JC, et al. JAMA 2010 303 1832 1840 10.1001/jama.2010.574 20460622
27. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Naj AC, Jun G, Beecham GW, Wang LS, Vardarajan BN, Buros J, Gallins PJ, Buxbaum JD, Jarvik GP, Crane PK, et al. Nat Genet 2011 43 436 441 10.1038/ng.801 21460841
28. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, Carrasquillo MM, Abraham R, Hamshere ML, Pahwa JS, Moskvina V, et al. Nat Genet 2011 43 429 435 10.1038/ng.803 21460840
29. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Satake W, Nakabayashi Y, Mizuta I, Hirota Y, Ito C, Kubo M, Kawaguchi T, Tsunoda T, Watanabe M, Takeda A, et al. Nat Genet 2009 41 1303 1307 10.1038/ng.485 19915576
30. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Simon-Sanchez J, Schulte C, Bras JM, Sharma M, Gibbs JR, Berg D, Paisan-Ruiz C, Lichtner P, Scholz SW, Hernandez DG, et al. Nat Genet 2009 41 1308 1312 10.1038/ng.487 19915575
31. Finding the missing heritability of complex diseases. Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, Hunter DJ, McCarthy MI, Ramos EM, Cardon LR, Chakravarti A, et al. Nature 2009 461 747 753 10.1038/nature08494 19812666
32. Glutathione metabolism during aging and in Alzheimer disease. Liu H, Wang H, Shenvi S, Hagen TM, Liu RM, Ann N Y Acad Sci 2004 1019 346 349 10.1196/annals.1297.059 15247041 (Pubitemid 38951332)
33. Pathway mapping tools for analysis of high content data. Ekins S, Nikolsky Y, Bugrim A, Kirillov E, Nikolskaya T, Methods Mol Biol 2007 356 319 350 16988414
34. Characterization of the monomethylarsonate reductase and dehydroascorbate reductase activities of Omega class glutathione transferase variants: implications for arsenic metabolism and the age-at-onset of Alzheimer's and Parkinson's diseases. Schmuck EM, Board PG, Whitbread AK, Tetlow N, Cavanaugh JA, Blackburn AC, Masoumi A, Pharmacogenet Genomics 2005 15 493 501 10.1097/01.fpc.0000165725.81559.e3 15970797 (Pubitemid 41017598)
35. Characterization of the human Omega class glutathione transferase genes and associated polymorphisms. Whitbread AK, Tetlow N, Eyre HJ, Sutherland GR, Board PG, Pharmacogenetics 2003 13 131 144 10.1097/00008571-200303000-00003 12618591 (Pubitemid 36324243)
36. The glutathione transferase structural family includes a nuclear chloride channel and a ryanodine receptor calcium release channel modulator. Dulhunty A, Gage P, Curtis S, Chelvanayagam G, Board P, J Biol Chem 2001 276 3319 3323 10.1074/jbc.M007874200 11035031
37. SNAP: a web-based tool for identification and annotation of proxy SNPs using HapMap. Johnson AD, Handsaker RE, Pulit SL, Nizzari MM, O'Donnell CJ, de Bakker PI, Bioinformatics 2008 24 2938 2939 10.1093/bioinformatics/btn564 18974171
38. High-resolution whole-genome association study of Parkinson disease. Maraganore DM, de Andrade M, Lesnick TG, Strain KJ, Farrer MJ, Rocca WA, Pant PV, Frazer KA, Cox DR, Ballinger DG, Am J Hum Genet 2005 77 685 693 10.1086/496902 16252231 (Pubitemid 41513273)
39. The PDGene Database. Alzheimer Research Forum. Lill CM, Roehr JT, McQueen MB, Kavvoura F, Bagade S, Schjeide BMM, Schjeide L, Meissner E, Zauft U, Allen NC, et al. Available at: http://www.pdgene.org/. Accessed [03-04-2012]
40. Gene expression levels as endophenotypes in genome-wide association studies of Alzheimer disease. Zou F, Carrasquillo MM, Pankratz VS, Belbin O, Morgan K, Allen M, Wilcox SL, Ma L, Walker LP, Kouri N, et al. Neurology 2010 74 480 486 10.1212/WNL.0b013e3181d07654 20142614
41. Association of common KIBRA variants with episodic memory and AD risk. Burgess JD, Pedraza O, Graff-Radford NR, Hirpa M, Zou F, Miles R, Nguyen T, Li M, Lucas JA, Ivnik RJ, et al. Neurobiol Aging 2011 32 557 e551 559
42. Association and heterogeneity at the GAPDH locus in Alzheimer's disease. Allen M, Cox C, Belbin O, Ma L, Bisceglio GD, Wilcox SL, Howell CC, Hunter TA, Culley O, Walker LP, et al. Neurobiol Aging 2012 33 203 e225 233
43. Apolipoprotein E epsilon4 count affects age at onset of Alzheimer disease, but not lifetime susceptibility: The Cache County Study. Khachaturian AS, Corcoran CD, Mayer LS, Zandi PP, Breitner JC, Arch Gen Psychiatry 2004 61 518 524 10.1001/archpsyc.61.5.518 15123497 (Pubitemid 38620851)
44. Interleukin-1 gene -511 CT polymorphism and the risk of Alzheimer's disease in a Polish population. Klimkowicz-Mrowiec A, Marona M, Wolkow P, Maruszak A, Styczynska M, Barcikowska M, Zekanowski C, Szczudlik A, Slowik A, Dement Geriatr Cogn Disord 2009 28 461 464 10.1159/000259460 19940477
45. APOE epsilon 4 lowers age at onset and is a high risk factor for Alzheimer's disease; a case control study from central Norway. Sando SB, Melquist S, Cannon A, Hutton ML, Sletvold O, Saltvedt I, White LR, Lydersen S, Aasly JO, BMC Neurol 2008 8 9 10.1186/1471-2377-8-9 18416843 (Pubitemid 351676569)
46. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM, Neurology 1984 34 939 944 10.1212/WNL.34.7.939 6610841 (Pubitemid 14076461)
47. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, Myers RH, Pericak-Vance MA, Risch N, van Duijn CM, JAMA 1997 278 1349 1356 10.1001/jama.1997.03550160069041 9343467 (Pubitemid 27449696)
48. Association of late-onset Alzheimer's disease with genetic variation in multiple members of the GAPD gene family. Li Y, Nowotny P, Holmans P, Smemo S, Kauwe JS, Hinrichs AL, Tacey K, Doil L, van Luchene R, Garcia V, et al. Proc Natl Acad Sci USA 2004 101 15688 15693 10.1073/pnas.0403535101 15507493 (Pubitemid 39473549)
49. Exploring the association of glyceraldehyde-3-phosphate dehydrogenase gene and Alzheimer disease. Lin PI, Martin ER, Bronson PG, Browning-Large C, Small GW, Schmechel DE, Welsh-Bohmer KA, Haines JL, Gilbert JR, Pericak-Vance MA, Neurology 2006 67 64 68 10.1212/01.wnl.0000223438.90113.4e 16832079 (Pubitemid 44305463)
50. Association of common KIBRA variants with episodic memory and AD risk. Burgess JD, Pedraza O, Graff-Radford NR, Hirpa M, Zou F, Miles R, Nguyen T, Li M, Lucas JA, Ivnik RJ, et al. Neurobiol Aging 2011 557 1 9
51. Genetic variation in PCDH11X is associated with susceptibility to late-onset Alzheimer's disease. Carrasquillo MM, Zou F, Pankratz VS, Wilcox SL, Ma L, Walker LP, Younkin SG, Younkin CS, Younkin LH, Bisceglio GD, et al. Nat Genet 2009 41 192 198 10.1038/ng.305 19136949
52. SNCA, MAPT, and GSK3B in Parkinson disease: a gene-gene interaction study. Wider C, Vilarino-Guell C, Heckman MG, Jasinska-Myga B, Ortolaza-Soto AI, Diehl NN, Crook JE, Cobb SA, Bacon JA, Aasly JO, et al. Eur J Neurol 2011 18 876 881 10.1111/j.1468-1331.2010.03297.x 21159074
53. Defining the Parkinson's disease phenotype: initial symptoms and baseline characteristics in a clinical cohort. Uitti RJ, Baba Y, Wszolek ZK, Putzke DJ, Parkinsonism Relat Disord 2005 11 139 145 10.1016/j.parkreldis.2004.10.007 15823477
54. Diagnostic criteria for Parkinson disease. Gelb DJ, Oliver E, Gilman S, Arch Neurol 1999 56 33 39 10.1001/archneur.56.1.33 9923759 (Pubitemid 29046907)
55. lumi: a pipeline for processing Illumina microarray. Du P, Kibbe WA, Lin SM, Bioinformatics 2008 24 1547 1548 10.1093/bioinformatics/btn224 18467348 (Pubitemid 351911712)
56. Model-based variance-stabilizing transformation for Illumina microarray data. Lin SM, Du P, Huber W, Kibbe WA, Nucleic Acids Res 2008 36 11 18178591
57. Meta-analysis in clinical trials. DerSimonian R, Laird N, Control Clin Trials 1986 7 177 188 10.1016/0197-2456(86)90046-2 3802833 (Pubitemid 17189972)
58. Novel late-onset Alzheimer's disease loci variants associate with brain gene expression. Allen M, Zou F, Chai HS, Younkin CS, Crook J, Pankratz VS, Carrasquillo MM, Rowley CN, Nair AA, Middha S, et al. Neurology 2012
59. PLINK: a tool set for whole-genome association and population-based linkage analyses. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, Sham PC, Am J Hum Genet 2007 81 559 575 10.1086/519795 17701901 (Pubitemid 47330214)
60. A second generation human haplotype map of over 3.1 million SNPs. Frazer KA, Ballinger DG, Cox DR, Hinds DA, Stuve LL, Gibbs RA, Belmont JW, Boudreau A, Hardenbol P, Leal SM, et al. Nature 2007 449 851 861 10.1038/nature06258 17943122 (Pubitemid 47598626)
61. Haploview: analysis and visualization of LD and haplotype maps. Barrett JC, Fry B, Maller J, Daly MJ, Bioinformatics 2005 21 263 265 10.1093/bioinformatics/bth457 15297300 (Pubitemid 40202029)